Castleview Partners’s QuidelOrtho QDEL Stock Holding History

Castleview Partners’s Portfolio QDEL Stock Details QDEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-811	Closed	-$91K	–	803
2022 Q1	$91K	Buy	+811	New	+$86.4K	0.06%	247

Other funds holding QDEL

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Castleview Partners's QDEL Position: Q2 2022 in Review

Castleview Partners sold out of QuidelOrtho (QDEL) in Q2 2022, closing a stake of 811 shares — an estimated $91K sold.

Castleview Partners first reported a position in QDEL in Q1 2022 and held it in 1 quarter. The position peaked at $91K in Q1 2022. 347 funds tracked by Wall St. Rank hold QDEL as of Q2 2022.

Castleview Partners reported no remaining QuidelOrtho position as of Q2 2022 after selling out during the quarter.
Castleview Partners sold 811 QuidelOrtho shares in Q2 2022, an estimated $91K.
Castleview Partners first reported a position in QuidelOrtho in Q1 2022 and held it in 1 quarter.
Castleview Partners's QuidelOrtho position peaked at $91K in Q1 2022.
347 funds tracked by Wall St. Rank held QuidelOrtho as of Q2 2022.

Based on Castleview Partners's 13F filing for Q2 2022, filed 16 Aug 2022.